QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Sernova Corp. (SVA.V) To Present At Upcoming Biotech Showcase 2013 Conference 0 comments
    Jan 4, 2013 10:58 AM | about stocks: SVA

    Sernova Corp., a clinical-stage health sciences company focused on commercializing medical technologies, announced it will be presenting at the Biotech Showcase 2013 Conference, taking place Jan. 7-9, 2013, at Parc 55 Wyndham San Francisco - Union Square in San Francisco, Calif. Sernova's presentation will be given on Monday, Jan. 7 at 1:45 p.m.

    Now in its fifth year, Biotech Showcase is an investor and partnering conference focused on providing private and public biotechnology and life sciences companies with the opportunity to meet with, and present to, investors and pharmaceutical executives in one location during one of the largest annual healthcare investor conferences in the industry. Investors and biopharmaceutical executives from across the globe gather in San Francisco each year for this important event.

    Sernova, a clinical-stage company developing products that provide a natural and immune-protected environment for delivering therapeutic cells to patients, is currently developing a platform technology for numerous serious disease indications, with its first therapeutic focus on insulin-dependent diabetes. The company is developing two novel, closely integrated proprietary platform technologies: Cell Pouch System, a scalable device that provides a natural, organ-like environment for therapeutic cells such as insulin-producing islets for diabetes; and Sertolin, which is a cell-based technology providing an immune-privileged environment for donor cells - reducing or eliminating the need for anti-rejection drugs. The company holds exclusive rights to multiple patents and associated intellectual property for the therapeutic use of Sertoli cells and has filed patents on the Cell Pouch System.

    Sernova's team is currently focused on developing the Cell Pouch System for treating insulin-dependent diabetes, which could benefit Type-1 and many Type-2 diabetes sufferers, and the company plans to commercialize products for Parkinson's, spinal cord injury, hemophilia, and other debilitating diseases. Leveraging a medical device and combination product strategy, Sernova takes part in the rapidly expanding cell therapy market and is positioned for significant growth and revenue as its paradigm-shifting technology progresses toward commercialization.

    For more information about Sernova, visit sernova.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: SVA
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.